Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Products, net		$ 843,769	$ 612,401	$ 455,865
Type of Revenue [Extensible List]		us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Collaboration and other		$ 89,244	$ 89,486	$ 84,234
Total revenues		933,013	701,887	540,099
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)		139,989	97,049	63,382
Research and development		877,090	771,182	722,343
Selling, general and administrative		451,421	282,660	317,875
Settlement and license charges		0	10,000	0
Amortization of in-licensed rights		714	706	662
Total cost and expenses		1,469,214	1,161,597	1,104,262
Operating loss		(536,201)	(459,710)	(564,163)
Other (loss) income, net:
Loss on debt extinguishment		(125,441)	0	0
Gain (loss) on contingent consideration, net*	[1]	6,700	7,200	(45,000)
Gain from sale of Priority Review Voucher		0	102,000	108,069
Other expense, net		(35,021)	(68,438)	(51,971)
Total other (loss) income, net		(153,762)	40,762	11,098
Loss before income tax (benefit) expense		(689,963)	(418,948)	(553,065)
Income tax expense (benefit)		13,525	(168)	1,063
Net loss		(703,488)	(418,780)	(554,128)
Other comprehensive loss:
Unrealized losses on investments, net of tax		(1,644)	(23)	(47)
Total other comprehensive loss		(1,644)	(23)	(47)
Comprehensive loss		$ (705,132)	$ (418,803)	$ (554,175)
Net loss per share - basic and diluted		$ (8.03)	$ (5.15)	$ (7.11)
Net loss per share - basic and diluted		$ (8.03)	$ (5.15)	$ (7.11)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share		87,559,000	81,262,000	77,956,000
Weighted average number of shares of common stock used in computing basic and diluted net loss per share		87,559,000	81,262,000	77,956,000

[1] * The gain (loss) on contingent consideration, net is related to the fair value adjustment of the regulatory-related contingent payments that are accounted for as derivatives. Please see Note 5. Fair Value Measurements for further details.